Moderna, Inc. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Moderna announced the creation of a Chief Operating Officer role effective October 5, 2026. Juan Andres, who previously served at Moderna from 2017–2023 in manufacturing and operations leadership, returns as COO reporting to CEO Stéphane Bancel. Jerh Collins, who served as Chief Technical Operations and Quality Officer since January 2023, is retiring. The restructuring coincides with Moderna's oncology expansion, intismeran autogene launch preparation, and five-vaccine infectious disease franchise.
Why this rating
Leadership change with operational continuity; returning executive known to company; no financial impact disclosed; material but not trajectory-altering for $9.9B market-cap firm.
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.